Small and medium biotechs jump on obesity train
This year, competition in the obesity therapeutic landscape has ramped up as biotechs aim to follow the success of blockbuster…
31 Mar 2023
Hipra’s Covid-19 booster gets EMA nod and enters an uncertain landscape
The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine, Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19…
31 Mar 2023
Medicines Patent Pool broadens access to generic injectable PrEP for HIV
On March 30, ViiV Healthcare and Medicines Patent Pool (MPP), announced sublicensing agreements with the pharma manufacturers Aurobindo, Cipla and Viatris to produce generic forms of the long-acting cabotegravir used…
31 Mar 2023
GSK signs licence deal with Scynexis for fungal infection treatment
GSK has signed an exclusive licence agreement with Scynexis to commercialise and further develop Brexafemme (ibrexafungerp tablets) to treat fungal infection. Brexafemme has a wide spectrum of activity, including against…
31 Mar 2023
Moderna to set up new mRNA manufacturing facility in Kenya
Moderna has finalised an agreement with the government of the Republic of Kenya to establish an mRNA manufacturing facility in the country. The company will construct the new advanced mRNA…
30 Mar 2023
US FDA launches lupus consortium to confront drug development challenges
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research and the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) have launched the Lupus Research Alliance (LRA) in a…
30 Mar 2023
MSD secures full approval for Keytruda’s use in MSI-high solid tumours
On March 29, MSD or Merck &Co announced that the US Food and Drug Administration (FDA) has given Keytruda full approval for use in adult and paediatric patients with unresectable…